


A PRACTICAL HANDBOOK ON THE PHARMACOVIGILANCE OF MEDICINES USED IN THE TREATMENT OF TUBERCULOSIS

ENHANCING THE SAFETY OF THE TB PATIENT



World Health
Organization

A practical handbook
on the pharmacovigilance
of medicines used in
the treatment of
tuberculosis

ENHANCING THE SAFETY OF THE TB PATIENT



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data:

A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient

1. Drug monitoring. 2. Drug utilization review – methods.
3. Antitubercular agents – adverse effects. 4. Adverse drug reaction reporting systems. 5. Handbooks. I. World Health Organization.

ISBN 978 92 4 150349 5

(NLM classification: QV 771)

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by minimum graphics
Printed in France

Contents

Abbreviations and acronyms	vi
Acknowledgements	viii
Preface: Why pharmacovigilance for anti-TB medicines?	ix
Key messages	x
A. Introduction	1
1. Pharmacovigilance	1
2. General aims	2
3. Specific aims	2
4. Pharmacovigilance centre (PvC)	3
B. Which approach to pharmacovigilance?	5
1. Spontaneous reporting	5
2. Targeted spontaneous reporting (TSR)	5
3. Active surveillance	5
C. Spontaneous reporting	7
1. Introduction	7
2. Objectives and methodology	7
3. Minimum reporting requirements	8
4. How to report	9
5. What to report	10
6. When to report	12
7. Who should report	12
8. Follow-up	12
9. Sharing the results	12
10. Data entry	13
D. Targeted spontaneous reporting (TSR)	14
1. Introduction	14
2. Objectives and methodology	14

E. Cohort event monitoring (CEM)	16
1. Introduction	16
2. Objectives and methodology	16
3. Implementation	19
4. Establishing the cohort(s)	20
5. Acquiring the data	22
6. Database for CEM	32
7. Maximizing the reporting rate	35
8. Practical advice and information	37
9. Clinical review	38
F. Data processing	43
G. Relationship and causality assessment	45
1. Background	45
2. Relationship (“objective phase”)	45
3. Categories of relationship	47
4. Processes for establishing the relationship	50
5. Causality (“subjective phase”)	52
H. Special types of event	53
1. Serious events	53
2. Pregnancy	53
3. Lactation exposure	55
4. Deaths	55
5. Lack of efficacy	55
6. Late onset reactions	56
7. Co-morbid conditions	56
I. Signal identification	57
1. Introduction	57
2. Selection criteria for events to investigate	58
3. Methods of signal identification	58

J. Evaluating a signal	62
1. General approach	62
2. Other experience	62
3. Searching for non-random patterns	63
4. Comparison with control events	63
5. Pharmacology	64
6. Undertaking epidemiological studies	64
7. Communication and feedback	64
K. Identifying risk factors	65
1. Introduction	65
2. Identification	65
L. Data description and analysis	67
M. Organization	70
1. Legislation	70
2. Ethical issues	71
3. Structure	74
4. Communication	76
Annexes	81
Annex 1. Useful websites and other resources	83
Annex 2. Form for spontaneous reports of suspected adverse drug reactions (ADRs) (Ghana)	90
Annex 3. Relationship between sample size and probability of observing an adverse event (AE)	91
Annex 4. Abbreviations for tuberculosis (TB) medicines and regimens	92
Annex 5. List of adverse drug reactions (ADRs) commonly associated with anti-tuberculosis (TB) medication	93
Annex 6. Treatment initiation form	94
Annex 7. Treatment review form	99
Annex 8. Tuberculosis identity card	104
Annex 9. Manual coding sheet	105
Annex 10. Major clinical categories in events dictionary	107
Annex 11. Decision tree for cohort event monitoring	108
Glossary	109

Abbreviations

ADRs	adverse drug reactions (to medicines, vaccines, herbal and traditional medicines)
AIDS	acquired immunodeficiency syndrome
ARV	antiretroviral
ATC	Anatomic Therapeutic Chemical Classification (for medicines)
BMI	body mass index
CEM	cohort event monitoring
CemFlow	electronic tool for data entry and analysis in cohort event monitoring
DD	(WHO) Drug dictionary
DF	dosage form (for combination therapy)
DOB	date of birth
DOTS	internationally agreed strategy for TB control
E	ethambutol
E2B	standardized data elements for transmission of ICSRs
FDC	fixed dose combination
GFATM	Global Fund to Fight AIDS, TB and Malaria

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28506

